US priority review for AZ’ bladder cancer drug
US regulators are undertaking a speedy review of AstraZeneca’s application to market durvalumab for patients with bladder cancer.
Read More
Tag: MEDI1814
- Cure Parkinson’s convenes expert panel to assess £2 million combination therapy funding call
- Kygevvi approved in Europe as first treatment for TK2d
- Tozorakimab shows significant benefit in two major COPD trials
- Daratumumab becomes first oncology injectable approved for patient administration
- Laigo Bio completes final close of €17m seed financing round
